文献速递主动脉疾病

终末期肾病患者胸主动脉开放手术与TEVAR术后死亡率均高

High mortality rates after both open surgical and endovascular thoracic aortic interventions in patients with end-stage renal disease.
PubMed 文献 · J Vasc Surg · 2017-04-08

基于美国肾脏数据系统2005至2008年352例透析依赖的终末期肾病患者,比较开放手术(136例)与TEVAR(216例)治疗胸主动脉疾病。

要点

  • 透析依赖ESRD患者胸主动脉开放手术30天死亡率为30.1%,TEVAR为15.7%。
  • TEVAR降低30天死亡风险(OR 0.41,95%CI 0.24-0.71),但无长期生存优势。
  • 两组估计1年生存率仅50%,择期干预仍属高风险,需谨慎。

核心结论

  • 在ESRD透析患者中,TEVAR较开放手术降低30天死亡率,但长期死亡率均高。
  • 该人群择期胸主动脉干预仍属高风险,应谨慎评估。

研究设计与样本

  • 回顾性队列研究,利用美国肾脏数据系统2005至2008年数据。
  • 纳入352例透析依赖ESRD患者,开放手术136例,TEVAR 216例。

主要发现

  • TEVAR组年龄大于开放组(68.2±11.5 vs 60.8±13.2岁,P<.001)。
  • 估计1年生存率50%,开放组44%,TEVAR组53%,组间无差异。

关键数值与推荐

  • TEVAR降低30天死亡风险的OR为0.41(95%CI 0.24-0.71)。

临床怎么用

  • 对透析依赖ESRD合并胸主动脉疾病患者,TEVAR可考虑用于降低短期死亡风险。
  • 择期干预需充分权衡高风险,谨慎选择病例。

局限性

  • 回顾性数据库研究,可能存在选择偏倚和未测量混杂。
  • 数据年份为2005至2008年,可能不代表当前实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Morbidity and mortality have improved with the evolution of endovascular techniques (thoracic endovascular aortic repair [TEVAR]) for thoracic aortic disease, but results after aortic intervention in patients with end-stage renal disease (ESRD) remain unclear. The objective of this study was to evaluate outcomes of open and endovascular descending thoracic aortic repair in dialysis-dependent patients. METHODS: We identified 352 patients with ESRD on dialysis undergoing open repair (n = 136) or TEVAR (n = 216) of the thoracic aorta from 2005 to 2008 using the United States Renal Data System database. Acute presentation was defined as ruptured aneurysm, dissection, or traumatic injury; all other interventions were considered elective. End points were 30-day mortality, overall survival, rates of perioperative complications, and procedural trends over time. Between-group comparisons and survival analysis used standard statistical methods. Logistic regression and Cox regression were performed using multivariate analysis. RESULTS: TEVAR subjects were older than those undergoing open repair (68.2 ± 11.5 vs 60.8 ± 13.2 years; P < .001); no other demographics differed. There were 303 patients who had thoracic or thoracoabdominal aneurysms; 47 (13.4%) were ruptured on presentation. There were 44 patients (12.5%) who had aortic dissection and 5 (1.4%) with aortic trauma. Overall 30-day mortality was 21.3% (n = 75), and it was greater for open repair (n = 41 [30.1%]) than for TEVAR (n = 34 [15.7%]; P = .002). Elective 30-day mortality for open repair (n = 27 [29.3%]) was also greater than for TEVAR (n = 24 [14.3%]; P = .005). Those with acute presentation trended toward higher mortality for open repair (n = 14 [31.8%] vs n = 10 [15.7%]; P = .17). Respiratory failure was higher for open repair (n = 69 [50.7%] vs n = 56 [25.9%]; P < .001); postoperative stroke was higher with TEVAR (n = 21 [9.7%] vs n < 10 [<7%]; P = .02). Estimated 1-year survival was 50% and did not differ between groups (44% for open repair, 53% for TEVAR). In multivariate analysis, TEVAR decreased odds of 30-day mortality compared with open repair (odds ratio, 0.41; 95% confidence interval, 0.24-0.71) but failed to demonstrate long-term survival advantage. CONCLUSIONS: In ESRD patients, TEVAR provides short-term mortality benefits compared with open repair, but long-term mortality remains high regardless of treatment modality. Elective intervention for thoracic aortic disease in this population remains high risk and should be approached with caution.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Liang NL, Yuo TH, Al-Khoury GE, et al. High mortality rates after both open surgical and endovascular thoracic aortic interventions in patients with end-stage renal disease. J Vasc Surg. 2017. PMID: 28400216. doi:10.1016/j.jvs.2016.12.144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。